Lactic acid bacteria: benefits, dosage, contraindications
Other name(s)
Probiotics
Family or group:
Probiotics
Active ingredients:
Lactobacilli
Bifidobacteria
Indications
Scoring methodology
EFSA approval.
Diarrhea ✪✪✪✪✪
Diarrhea can be caused by infections (viruses, parasites, bacteria), including acute diarrhea (gastroenteritis) and traveler's diarrhea caused by E. coli. Studies show that consuming at least 10 IU of lactic ferments (mixtures of lactobacilli and bifidobacteria) can prevent and/or treat (reduce the duration of) these diarrheas. Some clinical research shows that taking 250 mL of fermented milk containing a minimum of Lactobacillus rhamnosus GG 108 colony-forming units (CFU)/mL, Lactobacillus acidophilus La-5 107 CFU/mL, and Bifidobacterium Bb-12 108 CFU/mL orally every day for 14 days reduces the relative risk of antibiotic-associated diarrhea by 79% compared with the same dairy product containing heat-killed bacteria. Other clinical research shows that taking 49 grams of fermented milk containing at least 50 x 109 CFU of Lactobacillus acidophilus CL1285 and Lactobacillus casei (Bio-K+ CL1285, Bio-K+ International Inc) orally every day for 2 days, followed by 98 grams per day until the end of antibiotic treatment, reduces the relative percentage of patients suffering from antibiotic-associated diarrhea by 55% compared with placebo in hospitalized patients receiving systemic antibiotics. IU: billions of CFU
Posologie
Traveler's 'funny tummy' - reviewing the evidence for complementary medicine.
Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial
Prevention of antibiotic-associated diarrhea by a fermented probiotic milk drink
Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials.
Meta-analysis of probiotics for the prevention of traveler's diarrhea
Efficacy of probiotic use in acute diarrhea in children: a meta-analysis
Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis.
Probiotics for treating infectious diarrhea
Vaginal infections ✪✪✪✪✪
Vaginal infections (bacterial or Candida) are characterized by an imbalance of the vaginal flora. Studies have shown that standard treatments are more effective when accompanied by supplementation with lactic acid bacteria. Consumption of lactic acid bacteria reduces the risk of vaginal infections in pregnant women by 81%. A meta-analysis of 10 clinical studies conducted in patients with bacterial vaginosis shows that taking a probiotic alone or with antibiotics increases the chances of cure by 39% around day 30 after the intervention, compared with the control group. Various species of probiotics have been evaluated; it is not known exactly which species, if any, might be the most beneficial.
Posologie
Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomized placebo-controlled double-blind trial
Treatment of bacterial vaginosis with lactobacilli
Human lactobacilli as a supplement to clindamycin in patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study
Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomized, double-blind, placebo-controlled trial with microbiome analysis
Probiotics for the Treatment of Bacterial Vaginosis: A Meta-Analysis
Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis
Therapy of bacterial vaginosis using exogenously applied Lactobacillus acidophilus and a low dose of estriol: a placebo-controlled multicenter clinical trial
Eczema ✪✪✪✪✪
The intestinal microflora plays a major protective role against the development of allergy because it reduces the transport of antigens across the intestinal mucosa and helps induce oral tolerance. Consequently, probiotics may have a protective role in the prevention and/or management of atopic dermatitis and eczema due to their proposed actions. A number of clinical trials have investigated probiotic therapy to prevent the development of atopic eczema, and some have evaluated the effectiveness of probiotic therapy in the treatment of eczema. Pelucchi et al (2012) performed a meta-analysis of randomized controlled trials to determine whether the use of probiotics during pregnancy and early life reduces the incidence of atopic eczema and IgE-associated atopic eczema in infants and young children. Eighteen publications based on 14 studies were included in the analysis. The meta-analysis showed that probiotic use reduced the incidence of atopic dermatitis. Although the overall evidence supports the use of probiotics to reduce the incidence of atopic dermatitis in infants and young children, some strains were not effective. For example, the LAVRI-A1 strain of Lactobacillus acidophilus was not effective at reducing the incidence of developing atopic dermatitis. In another randomized, placebo-controlled, double-blind trial, the efficacy of Lactobacillus paracasei F-19 was evaluated. In this trial, the probiotic was administered to the infant (n = 179) directly at the time of weaning (mixed with food). The infants consumed the probiotic (1 × 10^8 CFU/day) from 4 to 13 months. Probiotic supplementation resulted in a significant reduction in cumulative incidence of eczema at 13 months and an improvement in the Th1/Th2 ratio. In another double-blind trial, women (n = 415) were randomized to receive either a placebo or a probiotic milk (containing Lactobacillus rhamnosus GG, Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12) from 36 weeks' gestation to 3 months postnatal during breastfeeding. Probiotic milk reduced the likelihood that the child would develop atopic dermatitis at age 6 by about 52% compared with placebo milk. No significant effect was observed on rates of asthma or atopic sensitization.
Posologie
Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome.
Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study
Children with atopic dermatitis show clinical improvement after Lactobacillus exposure.
Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood--a meta-analysis.
Physiological effect of a probiotic on skin
A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years.
Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis.
Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis
A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis.
Perinatal probiotic supplementation in the prevention of allergy-related disease: 6-year follow-up of a randomized controlled trial
Lactobacillus paracasei CNCM I-2116 (ST11) inhibits substance P-induced skin inflammation and accelerates skin barrier function recovery in vitro
Oral Lactobacillus paracasei improves skin barrier function recovery and reduces local skin inflammation
Cold ✪✪✪✪✪
A clinical study conducted among children aged 3 to 6 years attending daycare shows that taking a fermented dairy product containing Lactobacillus casei at a dose of 200 g per day for 3 months reduces the risk of developing a cold, the most common upper respiratory tract infection in these children, by about 18.5% compared with a control dairy product. In healthy, middle-aged male office workers, a preliminary clinical study shows that consumption of a fermented milk containing Lactobacillus casei Shirota for 12 weeks reduces the incidence and duration of the common cold by 59% compared with a control milk.
Posologie
Helicobacter pylori infection ✪✪✪✪✪
Oral probiotics, when added to most standard H. pylori eradication regimens, appear to be beneficial for improving eradication rates. Several meta-analyses show that taking probiotics in conjunction with standard H. pylori eradication therapy can increase eradication rates by 1.1 to 2 times compared with standard eradication therapy alone. Clinical research shows that Saccharomyces boulardii, Lactobacillus species, and bifidobacterial species may improve eradication rates. However, this effect appears to depend on the probiotic species or strain used, as well as on the eradication regimen. A meta-analysis shows the greatest benefit is obtained when a probiotic is added to quadruple therapies containing bismuth. Some research indicates that taking a combination of lactobacilli and bifidobacteria at the same time as the eradication treatment can double the eradication rate, while taking a probiotic containing lactobacilli alongside eradication therapy improves the eradication rate by 1.2. However, the effectiveness of lactobacillus appears to depend on the eradication regimen. Taking lactobacillus at the same time as an eradication regimen composed of a proton pump inhibitor, clarithromycin, and amoxicillin appears to improve eradication rates, but taking lactobacillus with a quadruple therapy, sequential therapy, or a therapy that does not include amoxicillin does not appear to improve eradication. Similarly, taking lactobacilli without antibiotics does not improve eradication rates in adults. Research on the use of yogurts or dairy products containing probiotics is more mixed.
Posologie
Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection
Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection
Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials.
Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication.
Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis
Lactobacillus gasseri Suppresses the Production of Proinflammatory Cytokines in Helicobacter pylori-Infected Macrophages by Inhibiting the Expression of ADAM17
Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells
Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal flora.
Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis
Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans
Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy
Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection
Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials
Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens
Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study
Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy.
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection
Irritable bowel syndrome ✪✪✪✪✪
Several species of probiotics have been evaluated to improve IBS symptoms. In general, clinical research shows that probiotics moderately improve IBS symptoms, particularly abdominal pain. The best evidence to date concerns a specific strain of bifidobacteria, called Bifidobacterium infantis 35624 (Align or Bifantis). Clinical research shows that taking this strain reduces abdominal pain, bloating and difficulty with bowel movements in the week following treatment. Clinical research also shows that daily intake of Bacillus coagulans for 56 to 90 days improves quality of life and reduces bloating, vomiting, abdominal pain and stool frequency compared with placebo. The American College of Gastroenterology conditionally recommends the use of probiotics, particularly combination probiotics, to improve overall symptoms, as well as bloating and flatulence, in patients with IBS.
Posologie
Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome
A meta-analysis of probiotic efficacy for gastrointestinal diseases
Meta-analysis of probiotics for the treatment of irritable bowel syndrome.
Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS
Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome.
Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials.
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review.
Respiratory infections ✪✪✪✪✪
Probiotics may be effective in strengthening the immune system and combating seasonal respiratory infections.nnA double-blind, placebo-controlled study was conducted on 479 healthy individuals for more than three months, who orally took a mixture of Lactobacillus. gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5. The aim was to clinically evaluate the influence of these probiotic strains in relieving the severity of symptoms and the duration of colds.nnThe results revealed that the group treated with probiotics showed a reduced duration of symptoms with milder symptoms. In addition, their cytotoxic T lymphocytes and CD8+ cells were significantly strengthened compared with the control group. nnThe study thus shows that L. gasseri, combined with other lactic cultures, reduces the duration and severity of symptoms of seasonal viral respiratory illnesses. nnPreliminary studies suggest that consumption of lactobacilli reduces the incidence of the common cold by about 12% in adults and reduces the incidence of respiratory disorders and infections in patients with cystic fibrosis from 37% to 3%. Certain strains of lactobacilli (rhamnosus GG) would notably reduce pulmonary exacerbations and hospital admission in children suffering from cystic fibrosis, notably through an anti-inflammatory action.nn
Posologie
Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study
Lactobacillus reuteri ATCC55730 in cystic fibrosis
Randomized, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body's immune defenses against viral infections.
Probiotic effects on cold and influenza-like symptom incidence and duration in children
Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers
A new opportunity to prevent winter illnesses through the administration of synbiotic formulations
Prospective study of probiotic supplementation shows immune stimulation and a reduced rate of upper respiratory infections
Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double-blind, randomized, controlled trial
Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial
Infant colic ✪✪✪✪✪
Clinical research shows that L. reuteri DSM 17938 may be beneficial for the TREATMENT of colic in breastfed infants. Administration of this specific strain for 21 to 28 days can reduce daily crying time in breastfed infants. Symptoms appear to improve within a week following treatment. In some clinical studies, the reduction in colic symptoms was greater in infants who received this strain than with simethicone 60 mg once or twice daily over a 28-day period. A meta-analysis of the available clinical research shows that probiotics do not appear to PREVENT the development of colic in infants. Research evaluating other Lactobacillus species or other probiotics is lacking.
Posologie
Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial
Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study
Antitussive effect of a fixed combination of Justicia adhatoda, Echinacea purpurea and Eleutherococcus senticosus extracts in patients with acute upper respiratory tract infection: A comparative, randomized, double-blind, placebo-controlled study
Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial
Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938
Probiotics to prevent infantile colic
Treating infant colic with the probiotic Lactobacillus reuteri: double-blind, placebo-controlled randomized trial
Constipation ✪✪✪✪✪
A meta-analysis of clinical research in adults with functional constipation shows that taking probiotics increases stool frequency compared with placebo.nnA specific probiotic species, L. reuteri DSM 17938 (BioGaia), has the strongest evidence of benefit. Other single-strain or combined probiotic products containing species of lactobacilli and/or bifidobacteria have also shown benefits in clinical research. Overall, the evidence for using probiotics to reduce constipation symptoms in adults is promising.nnHowever, because most available studies evaluate different probiotic strains, further research is needed to confirm which strains might be most beneficial.nnHowever, research conducted in children shows that taking probiotics does not improve constipation symptoms compared with placebo, as demonstrated by a meta-analysis of four clinical trials.nn
Posologie
Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defecation frequency and fecal characteristics of human volunteers
The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial.
Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomized, double-blind, placebo-controlled, parallel-group trial.
Systematic review and meta-analysis of the effect of probiotic supplementation on functional constipation in children
Randomized double-blind, placebo-controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation.
Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study
The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials
The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials.
Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study.
Allergic rhinitis ✪✪✪✪✪
Some clinical research shows that fermented milk may reduce certain symptoms of allergic rhinitis in adults. The consumption of 100 ml of heat‑treated fermented milk containing the L‑92 strain of Lactobacillus acidophilus (3 x 10^10 colony-forming units (CFU)/100 ml) per day for 8 weeks appears to reduce subjective nasal symptoms, but not ocular symptoms, compared with placebo in patients with allergic rhinitis. A clinical study conducted in adults suffering from allergic rhinitis caused by Japanese cedar pollen shows that the consumption of 80 ml of fermented milk containing the Shirota strain of Lactobacillus casei (4 x 10^8 colony-forming units (CFU)/ml) per day for 8 weeks does not improve allergic nasal symptoms compared with consumption of non‑fermented milk. Other studies suggest that fermented milk may also decrease the incidence of allergic rhinitis in children and adolescents. A clinical study conducted in preschool‑aged children with allergic rhinitis shows that taking 100 ml of fermented milk containing Lactobacillus casei, Lactobacillus bulgaricus and Streptococcus thermophilus orally once daily for 12 months reduces the annual number of rhinitis episodes by 1.6 compared with placebo. While other clinical research shows that consuming 200 to 400 ml of fermented milk containing Streptococcus thermophilus and Lactobacillus bulgaricus for 30 days does not improve allergic rhinitis symptoms in children and adolescents with allergic rhinitis, fortifying the product with Lactobacillus paracasei improves quality of life compared with consuming fermented milk that does not contain Lactobacillus paracasei. Fermented milk has also been studied for the prevention of allergic rhinitis in newborns. Clinical research conducted in pregnant women shows that consuming 250 ml of fermented milk containing Lactobacillus rhamnosus GG, Lactobacillus acidophilus and Bifidobacterium animalis during pregnancy, from the 36th week of gestation until 3 months after delivery, does not reduce the risk that the child will develop allergic rhinitis at age 6 years, compared with placebo milk.
Posologie
Treatment of perennial allergic rhinitis with lactic acid bacteria
Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study
Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical trial
A randomized prospective, double-blind, controlled trial on the effects of long-term consumption of fermented milk containing Lactobacillus casei in preschool children with allergic asthma and/or rhinitis
Chronic inflammatory bowel diseases ✪✪✪✪✪
Probiotics are used as an adjuvant therapy for Crohn's disease and ulcerative colitis. Overall, current research indicates a limited role for probiotics in Crohn's disease; results for ulcerative colitis are more promising, and there appears to be a beneficial effect on pouchitis (inflammation of the ileal pouch). Meta-analyses of clinical research show that taking probiotics increases the remission rate by a factor of 1.4 to 1.8 compared with placebo. The strongest evidence concerns a probiotic formulation containing species of lactobacilli, bifidobacteria, and streptococci (VSL#3). A meta-analysis also suggests that combination products containing bifidobacteria may be more effective than probiotics that do not contain bifidobacteria. Although a meta-analysis of three clinical trials shows that taking probiotics prevents relapses in 40% more patients than taking a placebo, most clinical research shows that probiotics containing lactobacilli or bifidobacteria, including VSL#3, do not prevent relapses in patients in remission. Given that most available studies are small and of low quality and that some have shown no benefit for induction of remission or prevention of relapses, further research is needed to confirm which probiotics, if any, might be beneficial for this use.
Posologie
The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis
Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis
A randomized double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis
Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials
Probiotics as an Adjunctive Factor in Active or Quiescent Inflammatory Bowel Disease in Adults: A Meta-Analytical Study
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalamine in the treatment of acute mild-to-moderate ulcerative colitis
Efficacy of Bifidobacterium breve fermented milk for maintaining remission in ulcerative colitis
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis
Properties
Gastroprotective




It has been found that a number of probiotic strains increase mucin production in the intestine by increasing expression of the mucin gene, which provides a protective coating between the lumen and the intestinal epithelial cells. Probiotics are also able to directly strengthen the intestinal barrier. A strain of Lactobacillus plantarum (WCSF1) has been found to decrease paracellular intestinal permeability by increasing the relocalization of occludin and zonulin proteins to the tight junction between duodenal epithelial cells. Occludin and zonulin are essential for keeping the cells of the intestinal wall tightly connected. Other strains appear to improve barrier function by preserving the cytoskeletal architecture of enterocytes and by strengthening the protein structures of the tight junction. These strains should prove useful in the treatment and prevention of intestinal permeability.
Usages associés
Antibacterial




In vitro research suggests that fermented dairy products contain antimicrobial compounds that inhibit the growth of Salmonella and Shigella. The lactic bacteria present in fermented dairy products can release compounds that prevent pathogenic bacteria from colonizing the digestive tract. It is thought that the probiotic can prevent pathogenic bacteria from finding a place on host tissue to attach and grow. For example, lactobacilli adhere to and colonize the intestinal or urogenital tracts, reducing epithelial attachment by pathogenic bacteria. Lactobacilli are thought to achieve this in part by increasing epithelial mucus production and by competing with pathogens for binding sites on the mucosa. According to human studies, regular consumption of fermented milk may reduce potentially pathogenic bacteria in the upper respiratory tract.
Usages associés
Immunomodulatory




A body of evidence indicates that certain probiotic strains are capable of modulating the immune system at both systemic and mucosal levels. Some probiotic strains can influence the immune system, affecting epithelial cells (lining cells), dendritic cells, and natural killer cells. They can stimulate the production of immunoglobulin A (IgA) and increase the activities of natural killer cells and macrophages. In addition, dendritic cells located in the submucosal tissue can interact with these probiotics to promote a balanced immune response. This includes the maturation of dendritic cells and the regulation of helper T-cell responses (Th1, Th2, Th3/Tr1).
Usages associés
Antiallergic




Orally
108 IU
fermented milk